China Resources Double-Crane Pharmaceutical Co Ltd Total Liabilities
China Resources Double-Crane Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has total liabilities worth CN¥4.85 Billion CNY (≈ $710.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check China Resources Double-Crane Pharmaceuti (600062) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)
Total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024. This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of China Resources Double-Crane Pharmaceuti to see how much of total assets are deployed in long-term investments.
China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Huace Navigation Technology Ltd
SHE:300627
|
China | CN¥1.64 Billion |
|
Hpsp Co Ltd
KQ:403870
|
Korea | ₩99.80 Billion |
|
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
|
China | CN¥40.16 Billion |
|
Proximus NV
BR:PROX
|
Belgium | €8.79 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥9.50 Billion |
|
Fujian Newland Computer Co Ltd
SHE:000997
|
China | CN¥7.76 Billion |
|
Civitas Resources Inc
NYSE:CIVI
|
USA | $8.43 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
USA | $2.03 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see China Resources Double-Crane Pharmaceuti (600062) total assets.
Liquidity & Leverage Metrics
China Resources Double-Crane Pharmaceutical Co Ltd Total Liabilities Ratios Explained
China Resources Double-Crane Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Double-Crane Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.57 Billion ≈ $815.69 Million |
+53.09% |
| 2023-12-31 | CN¥3.64 Billion ≈ $532.82 Million |
-2.98% |
| 2022-12-31 | CN¥3.75 Billion ≈ $549.17 Million |
+17.30% |
| 2021-12-31 | CN¥3.20 Billion ≈ $468.19 Million |
+5.26% |
| 2020-12-31 | CN¥3.04 Billion ≈ $444.77 Million |
+16.89% |
| 2019-12-31 | CN¥2.60 Billion ≈ $380.51 Million |
+8.46% |
| 2018-12-31 | CN¥2.40 Billion ≈ $350.84 Million |
+50.85% |
| 2017-12-31 | CN¥1.59 Billion ≈ $232.57 Million |
+32.11% |
| 2016-12-31 | CN¥1.20 Billion ≈ $176.04 Million |
-9.49% |
| 2015-12-31 | CN¥1.33 Billion ≈ $194.50 Million |
+42.17% |
| 2014-12-31 | CN¥934.93 Million ≈ $136.81 Million |
-18.32% |
| 2013-12-31 | CN¥1.14 Billion ≈ $167.50 Million |
-36.44% |
| 2012-12-31 | CN¥1.80 Billion ≈ $263.55 Million |
+3.89% |
| 2011-12-31 | CN¥1.73 Billion ≈ $253.69 Million |
+35.49% |
| 2010-12-31 | CN¥1.28 Billion ≈ $187.24 Million |
+8.24% |
| 2009-12-31 | CN¥1.18 Billion ≈ $172.99 Million |
+5.69% |
| 2008-12-31 | CN¥1.12 Billion ≈ $163.68 Million |
-14.53% |
| 2007-12-31 | CN¥1.31 Billion ≈ $191.52 Million |
+3.53% |
| 2006-12-31 | CN¥1.26 Billion ≈ $184.98 Million |
-32.55% |
| 2005-12-31 | CN¥1.87 Billion ≈ $274.23 Million |
-18.45% |
| 2004-12-31 | CN¥2.30 Billion ≈ $336.26 Million |
-9.57% |
| 2003-12-31 | CN¥2.54 Billion ≈ $371.86 Million |
+26.33% |
| 2002-12-31 | CN¥2.01 Billion ≈ $294.35 Million |
+60.12% |
| 2001-12-31 | CN¥1.26 Billion ≈ $183.83 Million |
+99.76% |
| 2000-12-31 | CN¥628.89 Million ≈ $92.03 Million |
+32.79% |
| 1999-12-31 | CN¥473.60 Million ≈ $69.30 Million |
+137.31% |
| 1998-12-31 | CN¥199.57 Million ≈ $29.20 Million |
+96.08% |
| 1997-12-31 | CN¥101.78 Million ≈ $14.89 Million |
+109.89% |
| 1996-12-31 | CN¥48.49 Million ≈ $7.10 Million |
+66.25% |
| 1995-12-31 | CN¥29.17 Million ≈ $4.27 Million |
-19.92% |
| 1994-12-31 | CN¥36.42 Million ≈ $5.33 Million |
-- |
About China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more